Tonix Pharmaceuticals Holdings CEO Dr. Seth Lederman shared with Steve Darling from Proactive that the company has secured an exclusive worldwide in-licensing agreement for TNX-4800, a groundbreaking investigational therapy designed to provide seasonal protection against Lyme disease. The treatment is intended as a single subcutaneous dose administered in the spring to offer protection throughout the entire tick season, lasting into the fall. Originally developed by researchers at UMass Chan Medical School, TNX-4800 is being licensed to Tonix to advance its development and commercialization. This strategic acquisition represents a significant milestone in the company’s mission to expand its infectious disease pipeline with innovative solutions. Lederman emphasized that there are currently no FDA-approved vaccines or prophylactic treatments available to prevent Lyme disease, which remains the most prevalent vector-borne illness in the United States. Reported cases are rising annually, underscoring the urgent need for effective preventive measures. Tonix believes TNX-4800 offers a potentially transformative approach. The therapy is designed to provide protective immunity within just two days of administration and to maintain its protective effect through the full tick season. Unlike conventional vaccine approaches, TNX-4800 uses a novel mechanism of action: it blocks the maturation of Borrelia burgdorferi—the bacteria that cause Lyme disease—in the midgut of infected deer ticks. By delivering a well-characterized antibody directly, TNX-4800 has demonstrated the ability to block the transmission of major Borrelia genospecies from ticks to animals in preclinical studies. This unique, single-dose seasonal model could simplify Lyme disease prevention and deliver broad public health benefits, positioning Tonix Pharmaceuticals as a leader in next-generation infectious disease prophylaxis. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #MPOXVaccine #Smallpox #TNX801 #VaccineDevelopment #ClinicalTrials #PharmaceuticalNews #MedicalResearch #WHO #GlobalHealth #InfectiousDiseases #Biopharma #ProactiveInvestors #LymeDisease #TNX4800 #BiotechNews